Stories about Immunomedics Inc
Should Investors Consider This Biotech Takeover Target?
December 21, 2020
From Motley Fool
Gilead's New CEO Is Going All-In on Acquisitions
November 28, 2020
From Motley Fool
Week In Review: Three $300 Million Deals For China Biopharma
November 07, 2020
From Blogs - TalkMarkets
From ChinaBio® Today
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
October 23, 2020
From Benzinga
Gilead Sciences Gets FDA Approval For Covid-19 Treatment Remdesivir
October 22, 2020
Stocks That Hit 52-Week Highs On Thursday
October 22, 2020
From Benzinga
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
October 22, 2020
From Benzinga
Stocks That Hit 52-Week Highs On Wednesday
October 21, 2020
From Benzinga
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
October 21, 2020
From Benzinga
Stocks That Hit 52-Week Highs On Tuesday
October 20, 2020
From Benzinga
The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
October 20, 2020
From Benzinga
Stocks That Hit 52-Week Highs On Monday
October 19, 2020
From Benzinga
Stocks That Hit 52-Week Highs On Friday
October 16, 2020
From Benzinga
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
October 15, 2020
From Benzinga
Stocks That Hit 52-Week Highs On Wednesday
October 14, 2020
From Benzinga
If You Invested $1,000 in Gilead Sciences' IPO, This Is How Much Money You'd Have Now
October 11, 2020
From Motley Fool
Is Gilead Sciences a Buy?
October 11, 2020
From Motley Fool
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
September 24, 2020
From Benzinga
The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix
September 20, 2020
From Benzinga
Cytodyn's Update Provides A Clear Path Towards Approval With Up-Listing Potential Still In The Cards
September 18, 2020
From Blogs - TalkMarkets
ETF Wrap: How to think about – and play – the wave of M&A activity
September 17, 2020
From MarketWatch
From MarketWatch
Benzinga's Top Upgrades, Downgrades For September 15, 2020
September 15, 2020
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.